Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-08-31
1999-09-07
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 7, 514789, 530352, 530359, 424417, 424450, 424460, A61K 3800
Patent
active
059487569
ABSTRACT:
A lipoprotein particle and a therapeutic lipoprotein composition are disclosed. The lipoprotein particle consists essentially of lecithin phospholipids with low phase transition temperatures and human apoproteins A and C. A therapeutic composition for therapeutic administration to a subject, comprising the lipoprotein particles of the invention, is also disclosed. The composition is useful is treating disease conditions associated with elevated serum Lp(a) levels, as well as hypertension and acute renal failure.
REFERENCES:
patent: 5128318 (1992-07-01), Levine et al.
patent: 5622715 (1997-04-01), Barenholz et al.
Szoka et al. (1980) Ann. Rev. Biophys. Bioeng. 9:467-508. Comparative Proties and Methods of Preparation of Lipid Vesicles (Liposomes).
Tall, A.R. (1980) J. Lipid Res. 21:354-363. Studies on the Transfer of Phosphatidylcholine from Unilamellar Vesicles into Plasma High Density Lipoproteins in the Rat.
Mallory et al. (1987) J. Biol. Chem. 262:9, pp. 4241-4247. Expression and Characterization of Human Apolipoprotein A-I in Chinese Hamster Ovary Cells.
Holtfretter et al. (1988) Biol. Chem. Hoppe Seyler. 369:1045-1054.
"Increased Concentrations of Serum Lp(a) Lipoprotein in Patients With Primary Gout"--Annals of the Rheumatic Diseases 1995; 54: 90-93; Takahashi et al.
"Serum Lipoprotein (a) Levels Before and After Subtotal Thyroidectomy in Subjects with Hyperthyroidism"--Metabolism, vol. 44, No. 1 (Jan.), 1995: pp. 4-7; Yamamoto et al.
"Elevated Serum Lp(a) Levels in the Early and Advanced Stages of Breast Cancer"--Cancer Biochem. Biophys., 1994, vol. 14, pp. 133-136; Kokoglu et al.
"Lipoprotein(a) in Type 1 Diabetic Patents with Renal Disease"--Diabetic Medicine (United Kingdom), vol. 11, No. 10, pp. 961-967, 1994 Groop et al.
"Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty by Reducing Lipoprotein (a) Levels with Low-Density Lipoprotein Apheresis"--The American Journal of Cardiology, Jun. 1, 1994, vol. 73, No. 15; pp. 1037-1040; Daida et al.
"Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein"--1986 Biochem. Biophys. Res. Commun. 875 = 183-194 (1986); Williams et al.
U.S. application No. 08/257,866, filed Jun. 10, 1994 entitled "Method of Treating Hypertension."
DeLamatre et al. (1986) Biochim. Biophys. Acta, vol. 875, pp. 419-428, 1986.
Davidson et al. (1995) J. Biol. Chem. vol. 270, No. 29, pp. 17106-17113, 1995.
Stein et al. (1975) Biochim. Biophys. Acta, vol. 380, pp. 106-118, 1975.
Holtfreter et al. (1988) Biol. Chem. Hoppe Seyler, 369:1045-1054.
Barenholz Yechezkel
Chajek Tova
Shmeeda Hilary
Longton Enrique D.
Wax Robert A.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Therapeutic lipoprotein compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic lipoprotein compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic lipoprotein compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1804578